Advertisement

Endocrine Pathology

, Volume 30, Issue 3, pp 219–236 | Cite as

Comprehensive Evaluation of Rare Pituitary Lesions: A Single Tertiary Care Pituitary Center Experience and Review of the Literature

  • Giulia Cossu
  • Jean-Philippe Brouland
  • Stefano La Rosa
  • Chiara Camponovo
  • Edoardo Viaroli
  • Roy Thomas Daniel
  • Mahmoud MessererEmail author
Article
  • 105 Downloads

Abstract

The 2017 World Health Organization classification of central nervous system and endocrine tumors have introduced significant changes in the diagnostic criteria for pituitary lesions. The aim of our paper is to describe the epidemiological, clinico-pathological, and radiological features of a single consecutive institutional surgical series of rare pituitary lesions, using these new criteria. Of the 316 endoscopic endonasal trans-sphenoidal approaches performed for pituitary lesions between 2010 and 2018, 15 rare lesions were encountered. These included metastases, pituitary carcinomas, pituicytomas, granular cell tumor, primary pituitary lymphomas, germinoma, mixed gangliocytoma–adenoma, hypophysitis, and pituitary hyperplasia. Their clinical, radiological, and pathological features are herewith presented along with a literature review that enabled us to propose an algorithm to facilitate a diagnosis for rare pituitary lesions.

Keywords

Pituitary lesion Rare disease Surgery Pathology Radiology 

Notes

Compliance with Ethical Standards

Conflict of Interest

None.

References

  1. 1.
    Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28:228–243CrossRefGoogle Scholar
  2. 2.
    Freda PU, Post KD (1999) Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 28:81–117, viCrossRefGoogle Scholar
  3. 3.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefGoogle Scholar
  4. 4.
    Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J, _ _ (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24:C5-C8CrossRefGoogle Scholar
  5. 5.
    Berhouma M, Messerer M, Jouanneau E (2012) Occam's razor in minimally invasive pituitary surgery: tailoring the endoscopic endonasal uninostril trans-sphenoidal approach to sella turcica. Acta Neurochir 154:2257–2265CrossRefGoogle Scholar
  6. 6.
    Kassam AB, Gardner PA, Snyderman CH, Carrau RL, Mintz AH, Prevedello DM (2008) Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellar craniopharyngiomas: a new classification based on the infundibulum. J Neurosurg 108:715–728CrossRefGoogle Scholar
  7. 7.
    Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16:E7CrossRefGoogle Scholar
  8. 8.
    Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115–121CrossRefGoogle Scholar
  9. 9.
    Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812CrossRefGoogle Scholar
  10. 10.
    La Rosa S, Uccella S (2019) Pituitary tumors: pathology and genetics. In: Boffetta P, Hainaut P (eds) Encyclopedia of cancer. 3rd edn. Elsevier, Academic Press, Cambridge pp 241–256Google Scholar
  11. 11.
    Cossu G, Daniel RT, Messerer M (2016) Gangliocytomas of the sellar region: a challenging diagnosis. Clin Neurol Neurosurg 149: 122–135CrossRefGoogle Scholar
  12. 12.
    Zada G. Lopes MBS, Mukundan S., Laws E (2016) Germ cell tumors of the sellar region. In: Zada G. LM, Mukundan S Jr, Laws E Jr (eds). Atlas of sellar and parasellar lesions. Springer, Berlin, pp 317–323CrossRefGoogle Scholar
  13. 13.
    Horowitz MB, Hall WA (1991) Central nervous system germinomas. A review. Arch Neurol 48:652–657CrossRefGoogle Scholar
  14. 14.
    Sano K (1999) Pathogenesis of intracranial germ cell tumors reconsidered. J Neurosurg 90:258–264CrossRefGoogle Scholar
  15. 15.
    Keene D, Johnston D, Strother D, Fryer C, Carret AS, Crooks B, Eisenstat D, Moghrabi A, Wilson B, Brossard J, Mpofu C, Odame I, Zelcer S, Silva M, Samson Y, Hand J, Bouffet E (2007) Epidemiological survey of central nervous system germ cell tumors in Canadian children. J Neurooncol 82:289–295CrossRefGoogle Scholar
  16. 16.
    Sawamura Y, de Tribolet N, Ishii N, Abe H (1997) Management of primary intracranial germinomas: diagnostic surgery or radical resection? J Neurosurg 87:262–266CrossRefGoogle Scholar
  17. 17.
    Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N, Seto T (1997) Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 86:446–455CrossRefGoogle Scholar
  18. 18.
    Packer RJ, Cohen BH, Cooney K (2000) Intracranial germ cell tumors. Oncologist 5:312–320Google Scholar
  19. 19.
    Brat DJ, Scheithauer BW, Staugaitis SM, Holtzman RNN, Morgello S, Burger PC (2000) Pituicytoma: a distinctive low-grade glioma of the neurohypophysis. Am J Surg Pathol 24:362–368CrossRefGoogle Scholar
  20. 20.
    Brat DJ, Scheithauer BW, Fuller GN, Tihan T (2007) Newly codified glial neoplasms of the 2007 WHO classification of tumours of the central nervous system: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol 17:319–324CrossRefGoogle Scholar
  21. 21.
    Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK (2009) Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J Neuropathol Exp Neurol 68:482–488CrossRefGoogle Scholar
  22. 22.
    Asa SL, Mete O (2018) What's new in pituitary pathology? Histopathology 72:133–141CrossRefGoogle Scholar
  23. 23.
    Shibuya M (2018) Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1 positive posterior pituitary tumors. Brain Tumor Pathol 35:62–72CrossRefGoogle Scholar
  24. 24.
    Komninos J, Vlassopoulou V, Protopapa D, Korfias S, Kontogeorgos G, Sakas DE, Thalassinos NC (2004) Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 89:574–580CrossRefGoogle Scholar
  25. 25.
    He W, Chen F, Dalm B, Kirby PA, Greenlee JD (2015) Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis. Pituitary 18:159–168CrossRefGoogle Scholar
  26. 26.
    Branch CL, Jr., Laws ER, Jr (1987) Metastatic tumors of the sella turcica masquerading as primary pituitary tumors. J Clin Endocrinol Metab 65:469–474CrossRefGoogle Scholar
  27. 27.
    Ruelle A, Palladino M, Andrioli GC (1992) Pituitary metastases as presenting lesions of malignancy. J Neurosurg Sci 36:51–54Google Scholar
  28. 28.
    Uccella S. MF, Amaglio C, Sessa F, La Rosa S (2019) The spectrum of lymphoproliferative disorders in endocrine organs: from histology to molecular genetics. Diagn Histopathol  https://doi.org/10.1016/j.mpdhp.2019.02.003, 25, 166, 177CrossRefGoogle Scholar
  29. 29.
    Tarabay A, Cossu G, Berhouma M, Levivier M, Daniel RT, Messerer M (2016) Primary pituitary lymphoma: an update of the literature. J Neurooncol 130:383–395CrossRefGoogle Scholar
  30. 30.
    Buxton N, Robertson I (2001) Lymphocytic and granulocytic hypophysitis: a single centre experience. Br J Neurosurg 15:242–245CrossRefGoogle Scholar
  31. 31.
    Abe T (2008) Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant. Brain Tumor Pathol 25:59–66CrossRefGoogle Scholar
  32. 32.
    Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR (2005) Autoimmune hypophysitis. Endocr Rev 26:599–614CrossRefGoogle Scholar
  33. 33.
    Bullmann C, Faust M, Hoffmann A, Heppner C, Jockenhövel F, Müller-Wieland D, Krone W (2000) Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis. Eur J Endocrinol 142:365–372CrossRefGoogle Scholar
  34. 34.
    Scheithauer BW, Silva AI, Atkinson JL, et al (2007) Pituitary adenoma with tumoral granulomatous reaction. Endocr Pathol 18:86–90CrossRefGoogle Scholar
  35. 35.
    Husain N, Husain M, Rao P (2008) Pituitary tuberculosis mimicking idiopathic granulomatous hypophysitis. Pituitary 11:313–315CrossRefGoogle Scholar
  36. 36.
    Duan K, Asa SL, Winer D, Gelareh Z, Gentili F, Mete O (2017) Xanthomatous hypophysitis is associated with ruptured Rathke's cleft cyst. Endocr Pathol 28:83–90CrossRefGoogle Scholar
  37. 37.
    Paulus W, Honegger J, Keyvani K, Fahlbusch R (1999) Xanthogranuloma of the sellar region: a clinicopathological entity different from adamantinomatous craniopharyngioma. Acta Neuropathol 97:377–382CrossRefGoogle Scholar
  38. 38.
    Leporati P, Landek-Salgado MA, Lupi I, Chiovato L, Caturegli P (2011) IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. Journal Clin Endocrinol Metab 96:1971–1980CrossRefGoogle Scholar
  39. 39.
    Anno T, Kawasaki F, Takai M, et al (2017) Clinical course of pituitary function and image in IgG4-related hypophysitis. Endocrinol Diabetes Metab Case Rep 2017. pii: 16–0148.  https://doi.org/10.1530/EDM-16-0148 Google Scholar
  40. 40.
    Bando H, Iguchi G, Fukuoka H, Taniguchi M, Yamamoto M, Matsumoto R, Suda K, Nishizawa H, Takahashi M, Kohmura E, Takahashi Y (2014) The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol 170:161–172CrossRefGoogle Scholar
  41. 41.
    Uccella S, Amaglio C, Brouland JP, Bianconi E, Ippolito S, Messerer M, Rouiller N, Tanda ML, Sessa F, la Rosa S (2019) Disease heterogeneity in IgG4-related hypophysitis: report of two histopathologically proven cases and review of the literature. Virchows Arch  https://doi.org/10.1007/s00428-019-02564-2
  42. 42.
    Peruzzotti-Jametti L, Strambo D, Sangalli F, et al (2012) Bilateral intracavernous carotid artery occlusion caused by invasive lymphocytic hypophysitis. J Stroke Cerebrovasc Dis 21:918 e919–918 e911CrossRefGoogle Scholar
  43. 43.
    Faje A (2016) Hypophysitis: Evaluation and Management. Clin Diabetes Endocrinol 2:15CrossRefGoogle Scholar
  44. 44.
    Caturegli P, Lupi I, Landek-Salgado M, Kimura H, Rose NR (2008) Pituitary autoimmunity: 30 years later. Autoimmun Rev 7:631–637CrossRefGoogle Scholar
  45. 45.
    Taylon C, Duff TA (1980) Giant cell granuloma involving the pituitary gland. Case report. J Neurosurg 52:584–587Google Scholar
  46. 46.
    Folkerth RD, Price DL Jr, Schwartz M, Black PM, De Girolami U (1998) Xanthomatous hypophysitis. Am J Surg Pathol 22:736–741CrossRefGoogle Scholar
  47. 47.
    Melmed S (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603–1618CrossRefGoogle Scholar
  48. 48.
    McNicol AM, Carbajo-Perez E (1999) Aspects of anterior pituitary growth, with special reference to corticotrophs. Pituitary 1:257–268CrossRefGoogle Scholar
  49. 49.
    De Sousa SM, Earls P, McCormack AI (2015) Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition. Endocrinol Diabetes Metab Case Rep 2015:150017Google Scholar
  50. 50.
    Pariante CM, Dazzan P, Danese A, et al (2005) Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology30:1923–1931CrossRefGoogle Scholar
  51. 51.
    Castelbaum AJ, Bigdeli H, Post KD, Freedman MF, Snyder PJ (2002) Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma. Fertil Steril 78:1311–1313CrossRefGoogle Scholar
  52. 52.
    Radner H, Pummer K, Lax S, Wandschneider G, Hofler H (1991) Pituitary hyperplasia after goserelin (LHRH-analogue) therapy. Neuropath Appl Neurobiol 17:75–81CrossRefGoogle Scholar
  53. 53.
    Horvath E, Kovacs K, Scheithauer BW (1999) Pituitary hyperplasia. Pituitary 1:169–179CrossRefGoogle Scholar
  54. 54.
    Al-Gahtany M, Horvath E, Kovacs K (2003) Pituitary hyperplasia. Hormones 2:149–158CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Giulia Cossu
    • 1
  • Jean-Philippe Brouland
    • 2
    • 3
  • Stefano La Rosa
    • 2
    • 3
  • Chiara Camponovo
    • 4
  • Edoardo Viaroli
    • 1
  • Roy Thomas Daniel
    • 1
    • 3
  • Mahmoud Messerer
    • 1
    • 3
    Email author
  1. 1.Department of NeurosurgeryLausanne University HospitalLausanneSwitzerland
  2. 2.Department of Clinical Pathology, Institute of PathologyLausanne University HospitalLausanneSwitzerland
  3. 3.University of LausanneLausanneSwitzerland
  4. 4.Department of EndocrinologyUniversity Hospital of LausanneLausanneSwitzerland

Personalised recommendations